samedan logo
 
 
 
spacer
home > ebr > summer 2003 > endurance: european biotech - surviving the storm
PUBLICATIONS
European Biopharmaceutical Review

Endurance: European Biotech - Surviving the Storm

'With the stock market upheaval ravaging the biotech industry, many opportunities have gone unexplored, many promising approaches have had no chance to prove themselves, and many good ideas have been left untested. At the same time, the assessment of biotech's potential has become more sober and pragmatic. The biotech industry is also more mature and is increasingly becoming part of the health care business mainstream. Better attuned to the realities, we can now more confidently pursue innovation in the service of better health care.'

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Reviewed by Dr Helen Abbott, Senior Consultant at Technomark Consulting Services Ltd and Editor of European Biopharmaceutical Review
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PPMA Show 2021 celebrates great success as it leads the way to build back business

The UKís largest processing and packaging machinery event returned to the NEC, Birmingham (28-30 September) following the cancellation of the 2020 Show. Hailed as a great success by exhibitors and visitors, over 250 exhibitors and 1,250 brands showcased the latest innovations in smart manufacturing, processing equipment and packaging solutions.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement